02  Liquid Biopsy Solutions from Telotech-
Circulating Tumor Cells (CTC)

The cornerstone of our liquid biopsy offering is our industry-leading CTC analysis. Using advanced isolation techniques and specific single cells surface biomarkers immunostaining, we are able to isolate and characterize these tumor-derived circulating cells by utilizing a high throughput robotic scanning platform.

 

By enumerating and profiling CTCs, our tests provide a real-time, holistic view of a patient's cancer. This liquid biopsy approach avoids the limitations of traditional tissue biopsies, revealing critical insights that can inform clinical decision-making at every stage of the cancer journey.

Our CTC analysis goes far beyond just counting the number of CTCs present. We leverage advanced genomic and phenotypic profiling to deliver a wealth of clinically actionable information, including:

 

- Identification of driver mutations and other genetic aberrations

- Evaluation of biomarkers associated with disease progression and treatment response

- Detection of emerging drug resistance mechanisms

- Monitoring of minimal residual disease

 

This comprehensive CTC profiling empowers clinicians to make more informed treatment decisions, optimize therapeutic strategies, and track a patient's response over time.

By placing the power of liquid biopsy in the hands of healthcare providers, Telotech is revolutionizing the way cancer is detected, monitored, and managed. Our CTC-based solutions have the potential to:

 

- Enable earlier cancer detection for improved patient outcomes

​

- Guide the selection of targeted therapies based on the unique tumor profile

​

- Monitor treatment response and detect disease recurrence sooner

​

- Accelerate the development of next-generation cancer therapeutics